Your browser doesn't support javascript.
loading
COX-2 Overexpression in Schneiderian Papillomas.
Suh, Jeffrey D; Hur, Kevin; Ference, Elisabeth H; Lam, David D; Fong, Andrew; Correa, Adrian J; Wrobel, Bozena.
Afiliación
  • Suh JD; Department of Head and Neck Surgery, University of California, Los Angeles, California.
  • Hur K; Caruso Department of Otolaryngology-Head and Neck Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • Ference EH; Department of Otolaryngology-Head and Neck Surgery, Northwestern University, Chicago, Illinois.
  • Lam DD; Caruso Department of Otolaryngology-Head and Neck Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • Fong A; Caruso Department of Otolaryngology-Head and Neck Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • Correa AJ; Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • Wrobel B; Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California.
Allergy Rhinol (Providence) ; 11: 2152656720973689, 2020.
Article en En | MEDLINE | ID: mdl-33343991
ABSTRACT

BACKGROUND:

Schneiderian papillomas (SP) are aggressive sinonasal tumors that occasionally extend into areas that are surgically unresectable.

OBJECTIVE:

evaluate the signifcance of cyclo-oxygenase-2 (COX-2) expression in SP.

METHODS:

Immunohistochemistry for COX-2 was performed on SP samples and middle turbinates from chronic rhinosinusitis without nasal polyps controls obtained during surgical resection between 2009-2017. A positive stain was defined as having 10% or more cells exhibiting diffuse immunoreactivity. Comparisons were performed using Fisher Exact tests, t-tests, and ANOVA.

RESULTS:

The study included 67 tumor samples and 9 controls from two academic institutions. The mean age of the SP group was 55.4 years and 53.2 years in the control group (p = 0.71). Thirty-nine (58.2%) SP patients had previous surgery compared to 1 (11.1%) in the control group (p = 0.01). The most common tumor attachment sites were the maxillary (47.8%) and ethmoid (25.4%) sinuses. Fifteen (22.4%) SP samples stained strongly positive for COX-2 and 24 (35.8%) stained weakly positive compared to no positive stains in the control group (p < 0.01). When stratified by COX-2 intensity, there were no statistically significant differences in gender, smoking history, history of previous sinus surgery, site of attachment, papilloma subtype, or future recurrence between SP samples.

CONCLUSION:

COX-2 was overexpressed in 58.2% of SP cases, and strongly positive in 22.4% of cases, compared to no positive staining among controls. No significant differences in COX-2 expression were observed between SP subtypes or recurrent tumors. Further studies are warranted to evaluate COX-2 as a possible therapeutic target in tumors that overexpress the enzyme.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Allergy Rhinol (Providence) Año: 2020 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Allergy Rhinol (Providence) Año: 2020 Tipo del documento: Article
...